ZA200907493B - [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof - Google Patents

[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Info

Publication number
ZA200907493B
ZA200907493B ZA200907493A ZA200907493A ZA200907493B ZA 200907493 B ZA200907493 B ZA 200907493B ZA 200907493 A ZA200907493 A ZA 200907493A ZA 200907493 A ZA200907493 A ZA 200907493A ZA 200907493 B ZA200907493 B ZA 200907493B
Authority
ZA
South Africa
Prior art keywords
quinazolin
thiophen
dioxo
methylamino
dihydro
Prior art date
Application number
ZA200907493A
Other languages
English (en)
Inventor
Emma Sharp
Louisa Jane Quegan
Anjali Pandey
Juan Wang
Matthew Nieder
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of ZA200907493B publication Critical patent/ZA200907493B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200907493A 2007-05-02 2009-10-26 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof ZA200907493B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02

Publications (1)

Publication Number Publication Date
ZA200907493B true ZA200907493B (en) 2010-07-28

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907493A ZA200907493B (en) 2007-05-02 2009-10-26 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Country Status (18)

Country Link
US (1) US20090042916A1 (enExample)
EP (1) EP2076510A2 (enExample)
JP (1) JP2010526105A (enExample)
KR (1) KR20100020455A (enExample)
CN (1) CN101720324A (enExample)
AU (1) AU2008247457A1 (enExample)
BR (1) BRPI0810800A2 (enExample)
CA (1) CA2686221A1 (enExample)
CO (1) CO6241155A2 (enExample)
EA (1) EA200901474A1 (enExample)
EC (1) ECSP099779A (enExample)
GT (1) GT200900282A (enExample)
IL (1) IL201829A0 (enExample)
MA (1) MA31397B1 (enExample)
MX (1) MX2009011836A (enExample)
TN (1) TN2009000452A1 (enExample)
WO (1) WO2008137809A2 (enExample)
ZA (1) ZA200907493B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use
WO2019126557A1 (en) * 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4574100B2 (ja) * 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ， インコーポレイテッド 血小板ａｄｐレセプターインヒビター
ATE502928T1 (de) * 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
AU2004278030C1 (en) * 2003-10-03 2010-12-02 Portola Pharmaceuticals, Inc. 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
KR20100029746A (ko) * 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
KR20100020455A (ko) 2010-02-22
CO6241155A2 (es) 2011-01-20
TN2009000452A1 (en) 2011-03-31
MA31397B1 (fr) 2010-05-03
MX2009011836A (es) 2010-05-20
CN101720324A (zh) 2010-06-02
WO2008137809A3 (en) 2009-01-22
US20090042916A1 (en) 2009-02-12
ECSP099779A (es) 2010-01-29
CA2686221A1 (en) 2008-11-13
IL201829A0 (en) 2010-06-16
EP2076510A2 (en) 2009-07-08
BRPI0810800A2 (pt) 2014-10-29
AU2008247457A1 (en) 2008-11-13
GT200900282A (es) 2010-05-21
JP2010526105A (ja) 2010-07-29
WO2008137809A2 (en) 2008-11-13
EA200901474A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
IL201829A0 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
IL237820A (en) Using a History of 4- (1-Carboxy-Ethylcarbamoyl) -4- (5- [2,1] Ditheolan-3-Il-Pentanoylamino) - Butyric Acid for Drug Preparation
SI2509963T1 (sl) Kristalinične oblike 3-(2,6-dikloro-3,5-dimetoksi-fenil)-1-(6-(4-4-etil-piperazin-1-il)- fenilamino)-pirimidin-4-il)-1-metil-uree in njenih soli
BRPI1012198A2 (pt) sais de dissacarina, ácido difumárico, ácido di-1-hidróxi-2-naftoico e ácido mono-benzoico de 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil) fenil) acetato de 4-(dimetilamino)butila
IL205742A0 (en) 4-(4-cyano-2-thioaryl)
ZA201001221B (en) 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ZA201003875B (en) Novel pyrimidine derivatives
ZA200907511B (en) Novel piperazine salts as D3/D2 antagonists
IL210447A0 (en) Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
IL184504A0 (en) 4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxylic acid piperidin-4-ylamid acid addition salts as kinase inhibitors
IL202038A0 (en) Rna antagonist compounds, compositions comprising the same and uses thereof
EP2139334A4 (en) CONDENSED HETEROCYCLIC 2-CYANOPHENYL COMPOUNDS AND COMPOSITIONS AND THEIR USE
SI2205593T1 (sl) Derivati kinazolindiona, njihova priprava in njihove terapevtske uporabe
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
IL195018A0 (en) Piperidinyl pyrimidine derivatives
PL2350026T3 (pl) Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek
EP1951254A4 (en) [(2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL] -5-CHLORO-THIOPHENE-2-YL-SULFONYLUREES [4- (6-HALO-7-SUBSTITUTEES)] AND ASSOCIATED FORMS AND METHODS
IL194549A0 (en) 2-(pyridin-2-yl)-pyrimidines for use as fungicides
IL201625A0 (en) Arylamide pyrimidone compounds
EP2094704A4 (en) CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES
PL2213669T3 (pl) Krystaliczna pochodna kwasu imidazolo-5-karboksylowego
ZA201002090B (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
IL205455A0 (en) 4 - [4 - (2 - adamantylcarbamoyl) - 5 tert - butyl - pyrazol - 1 - yl] benzoic acid - 465
ZA201002171B (en) 2-s-benzyl substituted pyrimidines as crth2 antagonists
GB0721013D0 (en) New Salts